Enliven Therapeutics (NASDAQ:ELVN) CFO Sells 6,018 Shares of Company Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $38.48, for a total transaction of $231,572.64. Following the transaction, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, September 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $50.35, for a total transaction of $303,006.30.
• On Monday, August 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $58.58, for a total transaction of $352,534.44.

Enliven Therapeutics Trading Up 1.4%

Shares of NASDAQ:ELVN traded up $0.57 during trading on Wednesday, hitting $41.82. 2,052,540 shares of the company’s stock were exchanged, compared to its average volume of 1,270,769. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32. The firm has a 50-day moving average price of $51.25 and a two-hundred day moving average price of $47.98. The firm has a market cap of $3.06 billion, a P/E ratio of -25.04 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, research analysts predict that Enliven Therapeutics, Inc. will post -1.81 EPS for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. increased its stake in shares of Enliven Therapeutics by 276.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock valued at $52,898,000 after acquiring an additional 847,399 shares during the last quarter. First Light Asset Management LLC raised its position in shares of Enliven Therapeutics by 574.1% in the 2nd quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock valued at $69,058,000 after acquiring an additional 1,158,883 shares during the period. Tidal Investments LLC raised its position in shares of Enliven Therapeutics by 27.7% in the 2nd quarter. Tidal Investments LLC now owns 60,694 shares of the company’s stock valued at $3,080,000 after acquiring an additional 13,179 shares during the period. WINTON GROUP Ltd acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $228,000. Finally, Engineers Gate Manager LP bought a new position in Enliven Therapeutics during the 2nd quarter worth approximately $1,479,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ELVN has been the subject of a number of analyst reports. The Goldman Sachs Group lifted their target price on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. HC Wainwright increased their price target on Enliven Therapeutics from $65.00 to $73.00 and gave the company a “buy” rating in a research note on Monday. JPMorgan Chase & Co. started coverage on Enliven Therapeutics in a research note on Thursday, October 1st. They issued an “overweight” rating and a $75.00 price target on the stock. Morgan Stanley started coverage on Enliven Therapeutics in a research report on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price target on the stock. Finally, Barclays initiated coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They issued an “overweight” rating and a $78.00 price target on the stock. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $75.44.

Key Enliven Therapeutics News

Here are the key news stories impacting Enliven Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy recommendation and $73 price objective for Enliven Therapeutics. The target indicates confidence in the company’s long-term pipeline and potential despite near-term losses.
• Neutral Sentiment: HC Wainwright estimates Enliven will report a $0.41 per-share loss in Q3 2026 and a $0.46 per-share loss in Q4 2026, resulting in a projected $1.74 loss per share for full-year 2026. The firm expects losses to continue through 2027, including $0.48 per share in Q1, $0.50 in Q2, $0.52 in Q3, and $0.55 in Q4.
• Negative Sentiment: The forecasts underscore that Enliven remains an unprofitable biotechnology company, with HC Wainwright projecting a $2.06-per-share loss for full-year 2027. Continued cash burn and the absence of near-term earnings could limit upside or increase sensitivity to clinical and financing developments.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.